

DEX-0315

BV

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 February 2003 (27.02.2003)

PCT

(10) International Publication Number
WO 03/016501 A2

(51) International Patent Classification⁷:

C12N

(21) International Application Number:

PCT/US02/26584

(22) International Filing Date:

21 August 2002 (21.08.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/314,023 21 August 2001 (21.08.2001) US

(71) Applicant (for all designated States except US):

THOMAS JEFFERSON UNIVERSITY [US/US];
Office of Technology Transfer, 1020 Locust Street, Room
M-60, Philadelphia, PA 19107-6799 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HOOPER, Douglas,
C. [CA/US]; 2 Oregon Trail, Medford, NJ 08055 (US). DI-
ETZSCHOLD, Bernhard [US/US]; 3430 Goshen Road,
Newtown Square, PA 19073 (US).

(74) Agent: MONACO, Daniel, A.; Drinker Biddle & Reath,
LLP, One Logan Square, 18th & Cherry Streets, Philadel-
phia, PA 19103-6996 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 03/016501 A2

(54) Title: RÉCOMBINANT ANTIBODIES, AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE
SAME

(57) Abstract: Recombinant antibodies are disclosed. The nucleic acid and encoded amino acid sequences of the heavy and light chain immunoglobulins of human monoclonal rabies virus neutralizing antibodies, and their use, are described.

rabies and rabies-related viruses associated with bats have recently been identified in the UK and Australia.

Rabies virus is characteristically bullet-shaped, enveloped particle of, on average, 75 by 180 nanometers. The virion consists of a single-stranded negative sense RNA genome and five structural proteins: the nucleoprotein (N) molecules, the phosphoprotein (NS), the polymerase (L), the matrix protein (M) and the viral glycoprotein (G).

- The N and G proteins both bear antigenic determinants which enable serotypic characterization of diverse rabies virus strains. N determinants are highly conserved between different virus isolates and are therefore very useful targets for the immunohistological detection of rabies virus infection using specific antibodies. On the other hand, antigenic determinants carried on the G-protein vary substantially among the rabies virus strains. Virus-neutralizing antibodies raised by vaccination with inactivated virus are directed against G. While it is clear that T cell responses to G, N, and NS, participate in immune responses to the virus under experimental conditions, assessment of immunity to rabies virus is generally limited to serology, particularly with respect to virus-neutralizing antibodies.

In areas of the world where human rabies is still common, the dog is the major reservoir of the viruses that infect man. Where canine rabies has largely been eliminated by vaccination, foxes, coyotes, skunks, raccoons, bats, and a variety of other mammals harbor variants of the virus. In many areas, wildlife reservoirs of virus continue to expand. Moreover, rabies virus can be transmitted from a reservoir species to humans or other end stage hosts by animals not normally associated with rabies, such as cats, rabbits, etc.

- Almost invariably fatal once clinical symptoms appear, rabies can be averted by prompt treatment of an infected individual with a combination of passive and active immunization. Passive immunization consists of the administration of pre-formed rabies virus neutralizing antibodies obtained from pooled serum of rabies immune individuals (Human rabies-immune globulin; HRIG) or hyper-immunized horses (Equine rabies-immune globulin; ERIG). Both types of reagent present certain risks to recipients including variable antigen specificity, and thus potency, for different rabies virus isolates.

HRIG is prepared from pooled human sera, therefore there is the possibility

heterologous expression systems. These constructs allow rabies neutralizing human antibodies of defined specificity to be produced in a controlled system, purified away from possible deleterious contaminants. The present invention relates to these monoclonal rabies virus neutralizing human antibodies, the nucleic acid sequences of their heavy and light chains and the amino acid sequences of the encoded proteins. Also provided in the present invention are methods of using the monoclonal antibodies as a therapeutically effective post-exposure prophylactic treatment of individuals exposed to rabies virus.

SUMMARY OF THE INVENTION

The present invention provides recombinant antibodies, and compositions for and methods of producing such antibodies. According to some aspects of the invention, the present invention provides recombinant anti-rabies antibodies, and compositions for and methods of producing such antibodies. According to some aspects of the invention, the present invention provides recombinant antibodies with a specific constant region that makes them particularly effective in combating pathogens which attack the neural system.

The present invention further relates to isolated DNA sequences, to recombinant vectors comprising such sequences, to host cells comprising such vectors and methods of producing recombinant antibodies using such host cells.

The present invention additionally relates to the use of recombinant antibodies in the diagnosis, prevention and treatment of pathogen infections of neuronal tissue, particularly rabies.

The present invention provides isolated nucleic acid molecules having a heavy chain and a light chain nucleic acid sequence encoding a heavy chain and a light chain amino acid sequence. The heavy chain and light chain amino acid sequences are that of a monoclonal rabies virus neutralizing antibody that specifically binds to a rabies virus protein.

The present invention provides isolated nucleic acid molecules that encode the monoclonal rabies virus neutralizing antibody are derived from cDNA sequences of the heavy chain SEQ. ID. NO:1 and the light chain SEQ. ID.:NO:2.

The present invention provides an isolated human monoclonal rabies virus

to the glycoprotein of various rabies virus strains. Post-exposure treatment with monoclonal antibody, or a mixture of a variety of monoclonal antibodies, will neutralize the rabies virus at the site of entry and prevent the virus from spreading to the central nervous system (CNS). Thus, for transdermal or mucosal exposure to rabies virus, rabies specific-monoclonal antibodies are instilled into the bite site, as well as administered systemically. Since viral replication is restricted almost exclusively to neuronal cells, neutralization and clearance of the virus by the monoclonal antibodies of the present invention prior to entry into the CNS is an effective post-exposure prophylactic.

One aspect of the present invention provides sequences of monoclonal antibodies against rabies virus. While most of the variable region of MAb 57 is well known (Cheung et al., *J. Virol.* 66:6714-6720, 1992, which is incorporated herein by reference), the constant region is not. The entire monoclonal antibody, both constant and variable regions, has been cloned and sequenced. The present invention provides the novel nucleotide sequence of MAb 57 constant region, nucleotides 476-1431, which includes 5 constant domain 1 (CH1) and the hinge region. This sequence may be used in recombinant antibodies including anti-rabies antibodies or recombinant antibodies directed 10 at other pathogens which attack neuronal tissue, such as encephalitis or herpes.

15

The invention relates to the recombinant antibodies, to the clones genes that encode them, to the vectors which incorporate cloned genes and host cells that include the 20 vectors. The invention also provides methods of making and using the recombinant antibodies.

The present invention provides recombinant antibodies derived from MAb 57. MAb 57 derived from hybridomas are IgG2 antibodies; recombinant antibodies derived from MAb 57 are IgG1 antibodies. The invention relates to the recombinant 25 antibodies derived from Mab 57, to the clones genes that encode them, to the vectors which incorporate cloned genes and host cells that include the vectors. The invention also provides methods of making and using the recombinant antibodies.

The present invention also provides the entire sequence of the heavy and light chains of the anti-rabies monoclonal antibody MAb JA. The invention relates to the 30 recombinant antibodies derived from Mab JA, to the clones genes that encode them, to the vectors which incorporate cloned genes and host cells that include the vectors. The

immobilized or entrapped cell culture, e.g. in hollow fibres, microcapsules, on agarose microbeads or ceramic cartridges.

Degenerated sequences are degenerated within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without resulting in a change of the amino acid sequence originally encoded. Such degenerated sequences may be useful due to their different restriction sites and/or frequency of particular codons which are preferred by the specific host, particularly *E. coli*, to obtain an optimal expression of the recombinant antibody.

Furthermore the invention concerns a recombinant DNA which is a hybrid vector comprising an insert coding for the recombinant antibody described hereinbefore, and, optionally an origin of replication or an autonomously replicating sequence, one or more dominant marker sequences, expression control sequences, signal sequences and additional restriction sites.

Vectors typically perform two functions in collaboration with compatible host cells. One function is to facilitate the cloning of the nucleic acid that encodes the immunoglobulin domains, i.e. to produce usable quantities of the nucleic acid (cloning vectors). The other function is to provide for replication and expression of the recombinant gene constructs in a suitable host, either by maintenance as an extrachromosomal element or by integration into the host chromosome (expression vectors). A cloning vector comprises the recombinant gene constructs as described above, an origin of replication or an autonomously replicating sequence, dominant marker sequences and, optionally, signal sequences and additional restriction sites. An expression vector additionally comprises expression control sequences essential for the transcription and translation of the recombinant genes.

An origin of replication or an autonomously replicating sequence is provided either by construction of the vector to include an exogenous origin such as derived from Simian virus 40 (SV 40) or another viral source, or by the host cell chromosomal mechanisms.

The markers allow for selection of host cells which contain the vector. Selection markers include genes which confer resistance to heavy metals such as copper or to antibiotics such as geneticin (G-418) or hygromycin, or genes which complement a

induced by isopropyl- β -D-thiogalactoside, the trp (tryptophan) promoter regulated by the trp repressor and induced e.g. by tryptophan starvation, and the tac (hybrid trp-lac promoter) regulated by the lac repressor.

- Vectors which are suitable for replication and expression in yeast contain a yeast replication start and a selective genetic marker for yeast. One group of such vectors includes so-called ars sequences (autonomous replication sequences) as origin of replication. These vectors are retained extrachromosomally within the yeast cell after the transformation and are replicated autonomously. Furthermore, vectors which contain all or part of the 2 μ m plasmid DNA from *Saccharomyces cerevisiae* can be used. Such vectors will get integrated by recombination into 2 μ m plasmids already existing within the cell, or replicate autonomously. 2 μ m sequences are particularly suitable when high transformation frequency and high copy numbers are to be achieved.

- Expression control sequences which are suitable for expression in yeast are, for example, those of highly expressed yeast genes. Thus, the promoters for the TRP1 gene, the ADH1 or ADH2 gene, acid phosphatase (PHO3 or PHO5) gene, isocytchrome gene or a promoter involved with the glycolytic pathway, such as the promoter of the enolase, glyceraldehyde-3-phosphate kinase (PGK), hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase and glucokinase genes, can be used.

- Vectors suitable for replication and expression in mammalian cells are preferably provided with promoting sequences derived from DNA of viral origin, e.g. from Simian virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus 2, bovine papilloma virus (BPV), papova-virus BK mutant (BKV), or mouse or human cytomegalovirus (CMV). Alternatively, the vectors may comprise promoters from mammalian expression products, such as actin, collagen, myosin etc., or the native promoter and control sequences which are normally associated with the desired gene sequence, i.e. the immunoglobulin H-chain or L-chain promoter.

- Some preferred vectors are suitable for both prokaryotic and eucaryotic hosts and are based on viral replication systems. Particularly preferred are vectors comprising Simian virus promoters, e.g. pSVgpt or pSVneo, further comprising an

with a hybrid vector according to the invention, and the transformed cells are selected. Transformation of microorganisms is carried out as described in the literature, for example for *S. cerevisiae* (A. Hinnen et al., Proc. Natl. Acad. Sci. USA 75: 1929, 1978), for *B. subtilis* (Anagnostopoulos et al., J. Bacteriol. 81: 741, 1961), and for *E. coli* (M. Mandel et al., J. Mol. Biol. 53: 159, 1970).

Accordingly, the transformation procedure of *E. coli* cells includes, for example, Ca^{2+} pretreatment of the cells so as to allow DNA uptake, and incubation with the hybrid vector. The subsequent selection of the transformed cells can be achieved, for example, by transferring the cells to a selective growth medium which allows separation of the transformed cells from the parent cells dependent on the nature of the marker sequence of the vector DNA. Preferably, a growth medium is used which does not allow growth of cells which do not contain the vector. The transformation of yeast comprises, for example, steps of enzymatic removal of the yeast cell wall by means of glucosidases, treatment of the obtained spheroplasts with the vector in the presence of polyethylene glycol and Ca^{2+} ions, and regeneration of the cell wall by embedding the spheroplasts into agar. Preferably, the regeneration agar is prepared in a way to allow regeneration and selection of the transformed cells as described above at the same time.

Transformation of cells of higher eucaryotic origin, such as mammalian cell lines, is preferably achieved by transfection. Transfection is carried out by conventional techniques, such as calcium phosphate precipitation, microinjection, protoplast fusion, electroporation, i.e. introduction of DNA by a short electrical pulse which transiently increases the permeability of the cell membrane, or in the presence of helper compounds such as diethylaminoethyl dextran, dimethyl sulfoxide, glycerol or polyethylene glycol, and the like. After the transfection procedure, transfected cells are identified and selected, for example, by cultivation in a selective medium chosen depending on the nature of the selection marker, for example standard culture media such as Dulbecco's modified Eagle medium (DMEM), minimum essential medium, RPMI 1640 medium and the like, containing e.g. the corresponding antibiotic.

The recombinant antibodies according to the invention can be used for the qualitative and quantitative determination of the presence of rabies virus. In general, the recombinant antibodies according to the invention can be used in any of the known

For immunostaining cryosections of cryopreserved biopsy material or paraffin embedded tissue sections are treated with a solution containing a recombinant antibody of the invention comprising a detectable enzyme. Bound recombinant antibody is detected by treatment with a suitable enzyme substrate, preferably an enzyme substrate which leads to a solid deposit (stain) at the site of the recombinant antibody of the invention. In place of recombinant antibodies comprising an enzyme, a recombinant antibody comprising streptavidin and a solution of a biotin-enzyme-conjugate may be used, which leads to higher enzyme concentration at the site of the antibody and hence increased sensitivity of the immunostaining method. The solid deposit of the enzyme substrate is detected by inspection with a microscope, for example with a fluorescence microscope, or by scanning the optical density at the wavelength of the stain.

The use according to the invention of recombinant antibodies as described hereinbefore for the determination of rabies virus also includes other immunoassays known per se, for example immunofluorescence assays, latex agglutination with antibody-coated or antigen coated latex particles, hemagglutination with antibody-coated or antigen-coated red blood corpuscles, evanescent light assays using an antibody-coated optical fibre and other direct-acting immunosensors which convert the binding event into an electrical or optical signal, or the like.

The invention also concerns test kits for the qualitative and quantitative determination of presence of rabies virus comprising recombinant antibodies of the invention and, optionally, adjuncts, positive and/or negative controls, buffers, instructions and descriptions of exemplary results.

Furthermore, the recombinant antibodies of the invention, in are useful for the prevention of rabies infection in patients suspected of possible exposure to rabies virus or the treatment of patients who have been infected with rabies.

The invention therefore also concerns pharmaceutical compositions comprising a therapeutically effective amount of a recombinant antibody according to the invention and a pharmaceutically acceptable carrier. Preferred are pharmaceutical compositions for parenteral application. Compositions for intramuscular, subcutaneous or intravenous application are e.g. isotonic aqueous solutions or suspensions, optionally prepared shortly before use from lyophilized or concentrated preparations. Suspensions in

were negative in tests for HIV and hepatitis B. The mouse-human hybrid heteromyeloma SHM-D33 cells utilized as hybridoma fusion partners (Teng, N.N. et al., *Proc. Natl. Acad. Sci. USA* 80, 7308, 1983) and B95-8 Epstein-Barr Virus (EBV)-transformed marmoset leukocytes used as a source of EBV (Henderson et al., *J. Exp. Med.* Vol. 76, p. 152, 1977)

5 were obtained from ATCC (Rockville, MD).

Rabies viruses

To assess the capacity of antibody preparations to neutralize a variety of rabies virus strains, a number of antigenically distinct fixed, laboratory strains, as well as two representative street rabies viruses, were used. Evelyn-Rokitnicki-Abelseth (ERA),
10 challenge virus standard, either mouse brain adapted (CVS-24) or cell culture adapted (CVS-11), and Pitman-Moore (PM) fixed strains were obtained from the Thomas Jefferson University virus collection. Silver-haired bat rabies virus (SHBRV), which has been associated with most of the recent rabies cases in the United States of America, and coyote street rabies virus/Mexican dog rabies virus (COSRV), which is a member of the dog
15 rabies viruses, were obtained as described (Morimoto et al., *Proc. Natl. Acad. Sci. USA*, Vol. 93, p. 5653, 1996). Virus purification and preparation of glycoprotein (G) and nucleoprotein (N) have been described elsewhere (Dietzschold et al., *World Health Organization*, Geneva, p. 175, 1996).

EBV-transformation of human PBLs

20 Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by density centrifugation on Ficoll-Paque (Amersham Pharmacia Biotech, Piscataway, NJ) as detailed elsewhere (Plebanski et al., *Immunology* Vol. 75, p. 86, 1992). T cells were then depleted by negative selection using monoclonal anti-CD2 antibody-coated magnetic beads (Dynal Inc., Lake Success NY) and a magnetic particle concentrator (Dynal). CD-2-negative cells, primarily B cells, were collected and immortalized as previously described (Swaminathan, 1992). Briefly, B95-8 cells, cultured to confluence in RPMI₁₆₄₀ (Gibco BRL Life Technologies, Grand Island NY) supplemented with 10% fetal bovine serum (FBS; Gibco), were lysed by freeze-thawing on dry ice to release intracellular EBV. Supernatant containing EBV was clarified by
25 spinning at 1000 RPM for 10 min and by filtration through a 0.45μm filter. Virus was concentrated by centrifugation at 8000 RPM for 2 h at 4°C. 7 X 10⁶ B cells (suspended in
30

minimum of three times by limiting dilution in microtiter plates. Cells were titrated in 96 well round bottom plates in 2-fold dilutions starting from 4 cells per well. Cells from wells containing an average of 0.25 cells or less were expanded for the collection of supernatant and further analysis.

5 *Analysis of rabies virus-specific antibodies in ELISA*

Antibody specificity and isotype was assessed in solid phase ELISA. Plates (PolySorb™, Nunc) were coated at room temperature in a humidified chamber overnight with 5*g/ml rabies ERA virus, glycoprotein, or nucleoprotein diluted in phosphate-buffered saline (PBS). The plates were then blocked with 5% powdered milk in PBS and 10 washed in PBS containing 0.05% Tween₂₀ (PBS-Tween) prior to the addition of supernatant samples.

Following incubation at room temperature for 2 h, the plates were washed with PBS-Tween to remove unbound primary antibody and various enzyme-conjugated or biotinylated secondary antibodies specific for the various human heavy chain isotypes 15 were added for 1 h at room temperature. Secondary antibody was detected either by the production of a soluble end product in the medium upon addition of the appropriate substrate (3,3',5,5'-tetramethylbenzidine (TMB) in phosphate-citrate buffer, or p-nitrophenyl phosphate (PNPP) in 0.1M glycine buffer, Sigma) or following the addition of avidin-alkaline phosphatase (30 min at RT) and PNPP substrate. The peroxidase-TMB 20 reaction was stopped by the addition of 2M H₂SO₄. Absorbance values were read in a microplate spectrophotometer (Biotek, Winooski VT) at 450 nm for the TMB product and at 405 nm for the PNPP reaction.

RFFIT

Supernatant samples from each transformed cell line were assayed for the 25 presence of rabies virus-neutralizing antibodies using a variation of the rapid fluorescent focus inhibition test (RFFIT) as previously described (Hooper, ASM Press, WA p. 1997). Supernatant samples (50 µl) were diluted in 96 well flat-bottom plates (Nunc). Rabies virus dilution known to cause 80-90% infection of the indicator cells were added to each test sample, and the plates incubated at 37°C for 1 h. Negative media and positive rabies 30 immune serum control samples were included in each assay. After incubation, 30µl of a 1.8 x 10⁶ cells/ml concentration of baby hamster kidney (BHK) cells were added to each

albumin (BSA) protein standards were included in each assay. After incubation, samples were read in a spectrophotometer at 595nm. Protein concentrations of test samples were calculated with reference to the absorbance of the BSA standards. The purity of all antibody preparations was assessed by electrophoresis in 12.5% polyacrylamide gel under 5 reducing conditions (SDS-PAGE). Purified antibodies showed two major bands on SDS-PAGE corresponding to isolated heavy and light immunoglobulin chains.

Generation, isolation and sequencing of cDNA clones

Total RNA was isolated from JA hybridoma cell by using RNazol B (Bioteclx Laboratories, Houston). Reverse transcriptase reactions were performed at 42°C 10 for 1 hr with avian myeloblastosis virus reverse transcriptase (Promega) and oligo(dT) primer. A portion of the reverse transcriptase products were subjected to polymerase chain reaction (PCR) amplification using heavy chain specific primers: IgG-HF1 primer (5'-ACCATGGAGTTGGCTGAG-3' (SEQ. ID.NO: 5), start codon; underline, accession # Y14737), and IgG-HR2 primer (5'-ACTCATTTACCCGGGGACAG-3' (SEQ. ID. NO: 6), 15 stop codon; underline, accession # Y14737) or light chain specific primers: IgG-LF5 primer (5'-AGCATTGGAAGCCCCAGCTCA-3' (SEQ. ID. NO: 7), start codon; underline, accession # M63438), and IgG-LR2 primer (5'-CTCTAACACTCTCCCCTGTTG-3' (SEQ. ID. NO: 8), stop codon, underline accession # M63438). Amplification was carried 20 out for 35 cycles of denaturation at 94°C for 60 seconds, annealing at 50°C for 60 seconds, and polymerization at 72°C for 90 seconds with Taq DNA polymerase (Promega). The PCR products (1.4 kb for heavy chain, .7 kb for light chain) were purified and sequenced by using the AmpliTaq cycle sequencing kit (Perkin-Elmer) with the specific primers. The PCR products were cloned into TA cloning vector, pCR2.1 (Invitrogen). The cloned 25 heavy chain and light chain cDNA was sequenced by using the AmpliTaq cycle sequencing kit (Perkin-Elmer) with the specific primers.

Monoclonal rabies virus neutralizing antibody coding sequences

Monoclonal antibody cDNA, and sequences complementary thereto, are 30 monoclonal antibody nucleic acids provided by the present invention. In a specific embodiment herein, a monoclonal antibody cDNA sequence is provided for the heavy chain (SEQ. ID. NO:1) and the light chain (SEQ. ID. NO:2) of the monoclonal antibody from clone JA, thus lacking any introns.

Sci. USA 85, 2444-2448, 1988. Chimerized antibodies have constant regions derived substantially or exclusively from human antibody constant regions and variable regions derived substantially or exclusively from the sequence of the variable region of a monoclonal antibody from each stable heterohybridoma (Champion, J.M., et al., *Journal*

5 *of Immunological Methods*, 235 81-90, 2000).

Single chain antibodies or Fv fragments are polypeptides that consist of the variable region of the heavy chain of the antibody linked to the variable region of the light chain, with or without an interconnecting linker. Thus, the Fv comprises the entire antibody combining site.

10 Functional equivalents further include fragments of antibodies that have the same, or substantially the same, binding characteristics to those of the whole antibody. Such fragments may contain one or both Fab fragments of the F(ab')_n.2 fragment. Preferably the antibody fragments contain all the complement determining region of the whole antibody, although fragments containing fewer than all of such regions, such as
15 three, four or five complement determining regions, are also functional. The functional equivalents are members of the IgG immunoglobulin class and subclasses thereof, but may be or may combine any one of the following immunoglobulin classes: IgM, IgA, IgD, or IgE, and subclasses thereof. Heavy chains of various subclasses, such as the IgG subclasses, are responsible for different effector functions and thus, by choosing the
20 desired heavy chain constant region, chimeric antibodies with desired effector function are produced. Preferred constant regions are gamma 1 (IgG1), gamma 3 (IgG3) and gamma 4 (IgG4). The light chain constant region can be of the kappa or lambda type.

The immunoglobulins of the present invention can be monovalent, divalent or polyvalent. Monovalent immunoglobulins are dimers (HL) formed of a chimeric heavy
25 chain associated through disulfide bridges with a chimeric light chain. Divalent immunoglobulins are tetramers (H₂ L₂) formed of two dimers associated through at least one disulfide bridge.

Standard recombinant DNA techniques

Standard recombinant DNA techniques are described in Sambrook et al.,
30 "Molecular Cloning," Second Edition, Cold Spring Harbor Laboratory Press (1987) and by Ausubel et al.(Eds) "Current Protocols in Molecular Biology," Green Publishing

The vector into which the monoclonal antibody cDNA is spliced may comprise segments of chromosomal, non-chromosomal and synthetic DNA sequences. Some suitable prokaryotic cloning vectors include, but are not limited to, plasmids from *E. coli*, such as colE1, pCR1, pBR322, pMB9, pUC, pKSM, and RP4. Prokaryotic vectors 5 also include, but are not limited to, derivatives of phage DNA such as M13 and other filamentous single-stranded DNA phages.

The vector containing the monoclonal antibody cDNA to be expressed is transfected into a suitable host cell, as described *infra*. The host cell is maintained in an appropriate culture medium, and subjected to conditions under which the cells and the 10 vector replicate.

Chimeric antibodies

In general, the chimeric antibodies are produced by preparing, for each of the light and heavy chain components of the chimeric immunoglobulin, a fused gene comprising a first DNA segment that encodes at least the functional portion of the human 15 rabies virus specific neutralizing, preferably glycoprotein, human variable region linked (e.g., functionally rearranged variable region with joining segment) to a second DNA segment encoding at least a part of human constant region. Each fused gene is assembled in or inserted into an expression vector. Recipient cells capable of expressing the gene products are then transfected with the genes. The transfected recipient cells are cultured 20 under conditions that permit expression of the incorporated genes and the expressed immunoglobulins or immunoglobulin chains are recovered.

Genes encoding the variable region of immunoglobulin heavy and light chains are obtained from lymphoid cells that produce the monoclonal rabies virus neutralizing antibodies. For example, the heterohybridoma cell lines that produce 25 monoclonal antibody against the rabies glycoprotein provide a source of immunoglobulin variable region for the present chimeric antibodies. Constant regions are obtained from human antibody-producing cells by standard cloning techniques. Alternatively, because genes are representing the two classes of light chains and the give classes of heavy chains have been cloned, constant regions of human origin are readily available from these 30 clones. Chimeric antibody binding fragments such as F(ab').sub.2 and Fab fragments are prepared by designing a chimeric heavy chain gene in truncated form. For example, a

functionally equivalent, gene product. The gene product itself may contain deletions, additions or substitutions of amino acid residues within a heavy or light chain sequence which result in a silent change, thus producing a functionally equivalent monoclonal antibody.

- 5 In accordance with the present invention, nucleotide sequences coding for heavy and light chains of the monoclonal rabies virus neutralizing antibody, a fragment or analog thereof, are inserted into an appropriate expression vector. This vector which contains the necessary elements for transcription and translation of the inserted protein-coding sequence so as to generate recombinant DNA molecules that direct the expression
10 of heavy and light chain immunoglobulins for the formation of monoclonal rabies virus neutralizing antibody.

The preferred recipient cell line is a myeloma cell. Myeloma cells can synthesize, assemble and secrete immunoglobulins encoded by transfected immunoglobulin genes. Further, they possess the mechanism for glycosylation of the
15 immunoglobulin. A particularly preferred recipient cell is a myeloma cell line that does not produce immunoglobulin, such as Sp2/0. These cell lines produce only the immunoglobulin encoded by the transfected immunoglobulin genes. Myeloma cells can be grown in culture or in the peritoneum of mice where secreted immunoglobulin can be obtained from ascites fluid. Other lymphoid cells such as B lymphocytes or hybridoma
20 cells can serve as suitable recipient cells.

Several methods exist for transfecting lymphoid cells with vectors containing immunoglobulin encoding genes. A preferred way of introducing DNA into lymphoid cells is by electroporation. In this procedure recipient cells are subjected to an electric pulse in the presence of the DNA to be incorporated. Another way to introduce
25 DNA is by protoplast fusion. In this method, lysozyme is used to strip cell walls from bacteria harboring the recombinant plasmid containing the immunoglobulin gene. The resulting spheroplasts are fused with myeloma cells with polyethylene glycol. After protoplast fusion, the transfectants are selected and isolated. Another technique that can be used to introduce DNA into many cell types is calcium phosphate precipitation.

30 The immunoglobulin genes can also be expressed in nonlymphoid cells, such as bacteria or yeast. When expressed in bacteria, the immunoglobulin heavy chains

CLAIMS

1. An isolated nucleic acid molecule comprising one or more nucleic acid sequences that encode an amino acid selected from the group consisting of: SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 and SEQ ID NO:16.
- 5 2. An isolated nucleic acid molecule of claim 1 comprising one or more nucleic acid sequences selected from the group consisting of: SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13 and SEQ ID NO:15.
3. A recombinant expression vector comprising a nucleic acid molecule of claim 2.
- 10 4. A host cell comprising an expression vector of claim 3.
5. A method of producing an isolated recombinant antibody comprising culturing a host cell of claim 4 and isolating recombinant antibodies expressed thereby.
6. A recombinant expression vector comprising a nucleic acid molecule of claim 1.
- 15 7. A host cell comprising an expression vector of claim 6.
8. A method of producing an isolated recombinant antibody comprising culturing a host cell of claim 7 and isolating recombinant antibodies expressed thereby.
9. A recombinant antibody comprising a constant region of Mab 57 linked to a non-MAb 57 variable region.
- 20 10. An isolated nucleic acid molecule that encodes the recombinant antibody of claim 9.

SEQUENCE LISTING

<110> Hooper, Douglas
Dietzschold, Bernhard

<210> 1
<211> 1430
<212> DNA
<213> Homo sapien

<400> 1

accatggagt	ttgggctgag	ctggctttt	cttggtggcta	ttttaaaagg	tgtcccaagtgt	60
gaggtgcacg	tggtggagtc	tgggggaggc	ttgttacagc	ctgggggggtc	cctgagactc	120
tcctgtcagc	cctctggatt	cacctttagc	aactatgcca	tgagctgggt	ccggccaggct	180
ccagggaaagg	ggctggagtg	ggtctcagct	attagtgtct	gtggtcatacg	cacatatttg	240
gcagactccg	tgaagggccg	gttaccatc	tccagagaca	attccaagaa	cacgctgtat	300
ctgcaaatga	acaggctgag	agccgaggac	acggccgtat	attactgtgc	gaaagatcga	360
gaggttacta	tgataatgt	acttaatgg	ggctttgact	actggggcca	gggaacccgg	420
gtcacccgtt	cctccgcctc	caccaagggc	ccatcggtct	tccccctggc	acccctctcc	480
aagagcacct	ctggggccac	agcggccctc	ggctgcctgg	tcaaggacta	cttcccggaa	540
ccggtgacgg	tgtcggtggaa	ctcaggcgcc	ctgaccagcg	gcgtgcacac	cttccggct	600
gtcctacagt	cctcaggact	ctactccctc	agcagcgtgg	tgaccgtgco	ctccagcagc	660
ttgggcaccc	agacctacat	ctgcaacgt	aatcacaagc	ccagcaacac	caagggtggac	720
aagagagtt	agcccaaatac	ttgtgacaaa	actcacacat	gcccacccgt	ccacgcaccc	780
gaactccctgg	ggggaccgtc	agtcttcctc	ttccccccaa	aacccaagga	caccctctatg	840
atctcccgaa	cccccgtggat	cacatgcgt	gtggtgacg	ttagccacga	agacccctgag	900
gtcaagttca	actgttacgt	gacggccgt	gaggtgcata	atgccaagac	aaagccggcg	960
gaggagcagt	acaacacgac	gtaccgtgt	gtcagcgtcc	tcacccgtct	gcaccaggac	1020
tggctgaatg	gcaaggagta	caagtgcacg	gtctccaaaca	aagccctccc	accccccatac	1080
gagaaaaacca	tctccaaagc	caaagggcag	ccccgagaac	cacaggtgta	caccctgccc	1140
ccatccccggg	aggagatgac	caagaaccag	gtcagcctga	cctgcctgg	caaaggcttc	1200
tatccccgg	acatcccggt	ggagtggag	agcaatggc	agccggagaa	caactacaag	1260
accacccctc	ccgtgctgga	ctccgacggc	tccttcttcc	tctatagcaa	gctcaccgtg	1320
gacaagagaca	ggtggcagca	ggggAACGTC	ttctcatgtc	ccgtgatgca	tgaggctctg	1380
cacaaccact	acacgcagaa	gaggccctcc	ctgtccccgg	gtaaaatgagt		1430

<210> 2
<211> 708
<212> DNA
<213> Homo sapien

275	280	285
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp		
290	295	300
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu		
305	310	315
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu		
325	330	335
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn		
340	345	350
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly		
355	360	365
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu		
370	375	380
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr		
385	390	395
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn		
405	410	415
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe		
420	425	430
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn		
435	440	445
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr		
450	455	460
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys		
465	470	

<210> 4
<211> 234
<212> PRT
<213> Homo sapien

<400> 4			
Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Trp Leu Pro			
1	5	10	15
Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser			
20	25	30	
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ala Cys Arg Ala Ser Gln Thr			
35	40	45	
Ala Ser Arg Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro			
50	55	60	
Arg Leu Leu Ile Tyr Asp Thr Ser Asn Arg Ala Thr Gly Ile Pro Ala			
65	70	75	80
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Ser			
85	90	95	
Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Phe			
100	105	110	
Asn Trp Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Phe Lys Arg			
115	120	125	
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln			
130	135	140	
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr			
145	150	155	160
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser			
165	170	175	
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr			

SEQ ID NO:9

ATGGACACACTTGTCCACGCTCCTGCTGACCATCCCTCATGGG
 TCTTGTCCAAATTACCTGAAGGAGACTGGTCTACGCTGGTAAACC
 CACACAGACCCCTCACGCTGACCTGCACCTTCTGGGGTCTCACTCAGC
 ACTAGTGGAGTGGGTGTGGGCTGGATCCGTAGCCCCCAGGAAGGCC
 CTGGAGTGGGTACACTCATTTATTGGGATGATGATAAGCGTTACAGTCC
 ATCTCTGGAGAACAGGGTCACCATCAGGAAGGACACCTCCAAAAACAG
 GTGGCTCTTACAATGACGAACATGGACCCCTTGGACACAGGCACATACT
 ACTGTGCCACAGACAACATATCAGCAGCTTCCCCTGGTCAAGGACTACTTCCCCGAGCCGGTGAC
 GGGCCAGGGAACCCCTGGTACCGTCTCTCAGCTTCCACCAAGGGCCC
 ATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCTGGGGGAC
 AGCGGCCCTGGGCTGCCCTGGTCAAGGACTACTTCCCCGAGCCGGTGAC
 GGTGTCGTGGAACTCAGGCCTGACCCAGGGGGCGTGCACACCTTCCC
 GGCTGTCTTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACC
 GTGCCCTCCAGCAGCTGGGACCCAGACCTACACCTGCAACGTGAATC
 ACAAGCCCAGCAACACCAAGGTGGACAAGAGAGGTGAGCTCAAACCCC
 ACTTGGTGACACAACATCACACATGCCACGGTGCCCAGAGCCCAAATCT
 TGTGACACACCTCCCCGTGCCACGGTGCCCAGAGCCCAAATCTGTG
 ACACACCTCCCCGTGCCACGGTGCCCAGAGCCCAAATCTGTGACAC
 ACCTCCCCATGCCACGGTGCCCAGCACCTGAACCTCTGGAGGACC
 GTCAGTCTTCTCTTCCCCAAAACCCAAGGATACTCTTATGATTCTCC
 GGACCCCTGAGGTCACTGCGTGGTGGACGTGAGCCACGAAGACC
 CCGAGGTCCAGTTCAAGTGGTACGTGGACGGCGTGGAGGTGCATAATG
 CCAAGACAAAGCCGGGAGGAGCAGTTCAACACAGCACGTTCCGTG
 TCAGCGTCTCACCCTGCACCAAGGACTGGCTGAACGTAAGGAGTA
 CAAGTCAAGGTCTCAACAAAGCCCTCCCAGCCCCATCGAGAAAACC
 ATCTCCAAAACCAAAGGACAGCCCCGAGAACCACAGGTGTACACCTGC
 CCCCACCCGGGAGGAGATGACCAAGAACCCAGGTCACTGACCTGCC
 TGGTCAAAGGCTTCTACCCCCAGCGACATGCCGTGGAGTGGAGAGCA
 GCGGGCAGCCGGAGAACAACTACAACACCACGCCCTCCATGCTGGACT
 CCGACGGCTCTCTACAGCAAGCTCACCGTGGACAAGAGCAG
 GTGGCAGCAGGGAACATCTCTCATGCTCCGTATGCACTGAGGCTCTG
 CACAACCGCTCACGCAGAAGAGCCTCCCTGCTCCGGTAAATGA

SEQ ID NO:10

MDTLCSTLLLTISSWVLSQITLKETGPTLVKPTQITLTCTFSGFSLSTSGVG
 VGWIRQPPGKALEWVTLIYWDKDCKRSPSLENRVTRKDTSKNQVALMTN
 MDPLDTGTYCAHRQHISFPWFDSWGQGTLVTVSSASTKGPSVFPLAPC
 SRSTSGGTAALGCLVKDYFPEPVTVWSNSGALTSGVHTFPAVLQSSGLYSL
 SSVTVPSLGLTQTYTCNVNHKPSNTKVDKVELKTPLGDTHTCPRCPE
 PKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAELLG
 GPSVFLPPPKDLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVVEVHNA
 KTKPREEQFNSTFRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTSKT
 KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPEN
 NYNTTPPMULDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRTQKS
 LSLSPGK

GAATGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCC
ATCGAGAAAACCATCTCAAAGCCAAAGGGCAGCCCCGAGAACCAACAGGTGTACACCTG
CCCCCATCCCAGGGAGGAGATGACCAAGAACCGAGTCAGCCTGACCTGCCTGGTCAAAGC
TTCTATCCCAGCGACATGCCGTGGAGTGGAGAGAGCAATGGCAGCCGGAGAACAACTAC
AAGACCACGCCTCCCGTGTGGACTCCGACGGCTCTCTCTATAGCAAGCTCACC
GTGGACAAGAGCAGGTGGCAGCAGGGAACGTCTCTCATGCTCCGTATGCATGAGGCT
CTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGTAAATGA

SEQ ID NO:16

MDWTWRFLFVVAATGVQSQVQLVQSGAEVKPGSSVKVSCKASGGTFNRYTVNWVRQA
PGQGLEWMGGIPIFGTANYAQRFQGRLTITADESTSTAYMELSSLRSDDTAVYFCARENLD
NSGTYYFSGWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSQLGTQTYICNVNHKPSNTKVDKRV
EPKSCDKTHTCP GPAPELLGGPSVFLFPPPKDLMISRTPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKA
KGQPREPVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK